About 13% of lung cancer cases are of the small cell subtype, but this variant is highly aggressive, and approximately 40% of patients with small cell lung cancer will have limited-stage disease, which is potentially curable with the combination of chemotherapy and radiation therapy. The standard therapy for limited-stage small cell lung cancer is concurrent chemoradiotherapy, and the 5-year survival rate observed in clinical trials is approximately 25%. For patients who obtain a near complete or complete response, prophylactic cranial irradiation (PCI) reduces the incidence of brain metastases and improves overall survival. However, chemotherapy has its limitations, the side effect caused by chemotherapy and radiotherapy is critical, so extending patient lifespan by using treatments with lower toxicities is necessary. TCM plays an important role in improving quality of life and a reduction in side effects. This may be of significant clinical value in prolonging patient's survival time.